Search
Climb Bio Inc
CLYMAdd to Watchlist
12.900USD
-0.390-2.93%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
616.21MMarket Cap
LossP/E TTM
More Details of Climb Bio Inc Company
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Climb Bio Inc Info
Ticker SymbolCLYM
Company nameClimb Bio Inc
IPO dateAug 10, 2021
CEOBrennan (Aoife M)
Number of employees17
Security typeOrdinary Share
Fiscal year-endAug 10
Address20 William Street
CityWELLESLEY HILLS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02481
Phone18668572596
Websitehttps://climbbio.com/
Ticker SymbolCLYM
IPO dateAug 10, 2021
CEOBrennan (Aoife M)
Company Executives of Climb Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Climb Bio Inc?
The top five shareholders of Climb Bio Inc are: Dr. Aoife M. Brennan
How many institutions hold shares of Climb Bio Inc (CLYM)?
As of 2026Q1, 194 institutions hold shares of Climb Bio Inc, with a combined market value of approximately 35.98M, accounting for 59.67% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -6593711.00.